Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis


Current price
17.83 USD +0.12 USD (+0.68%)
Last closed 17.92 USD
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 3 374 894 592 USD
Yield for 12 month +34.26 %
21.11.2021 - 28.11.2021

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Address: Cheung Kong Center, Central, Hong Kong


WallStreet Target Price

30.95 USD

P/E ratio

Dividend Yield

Current Year

+426 409 000 USD

Last Year

+356 128 000 USD

Current Quarter

+208 441 500 USD

Last Quarter

Current Year

+115 306 000 USD

Last Year

+97 894 000 USD

Current Quarter

+8 156 000 USD

Last Quarter

Key Figures HCM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -91 185 000 USD
Operating Margin TTM 20.95 %
PE Ratio
Return On Assets TTM -4.98 %
PEG Ratio
Return On Equity TTM -3.4 %
Wall Street Target Price 30.95 USD
Revenue TTM 757 235 968 USD
Book Value 0.92 USD
Revenue Per Share TTM 4.48 USD
Dividend Share
Quarterly Revenue Growth YOY 163.7 %
Dividend Yield
Gross Profit TTM -271 587 000 USD
Earnings Share -0.25 USD
Diluted Eps TTM -0.25 USD
Most Recent Quarter IV 2022
Quarterly Earnings Growth YOY
Profit Margin -3.89 %

Dividend Analytics HCM

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History HCM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:1
Payout Ratio
Last Split Date 30.05.2019
Dividend Date

Stock Valuation HCM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 3.1361
Price Sales TTM 4.4569
Enterprise Value EBITDA -25.4637
Price Book MRQ 4.1329

Financials HCM

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators HCM

For 52 weeks

10.68 USD 21.28 USD
50 Day MA 18.02 USD
Shares Short Prior Month 653 447
200 Day MA 15.08 USD
Short Ratio 2.64
Shares Short 524 031
Short Percent 1.9 %